Geretti; Elena

Patent Applications and Registrations

Patent applications and USPTO patent grants for Geretti; Elena.The latest application filed is for "methods and compositions for cancer immunotherapy".

Company Profile

0.3.15

Geretti; Elena - Cambridge MA
GERETTI; ELENA - CAMRIDGE MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods And Compositions For Cancer Immunotherapy App 20220008526 - Andresen; Thomas Lars ; et al.	2022-01-13
Combination therapy for treating HER2-positive cancers Grant 9,913,901 - Moyo , et al. March 13, 2	2018-03-13
Combination Therapies For Treating Her2-positive Cancers That Are Resistant To Her2-targeted Therapies App 20170258903 - Espelin; Christopher W. ; et al.	2017-09-14
Methods And Compositions For Improving Outcomes Of Liposomal Chemotherapy App 20170231911 - GERETTI; Elena ; et al.	2017-08-17
Dosage And Administration For Preventing Cardiotoxicity In Treatment With Erbb2-targeted Immunoliposomes Comprising Anthracycline Chemotherapeutic Agents App 20170189335 - Reynolds; Joseph G. ; et al.	2017-07-06
Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents Grant 9,610,249 - Reynolds , et al. April 4, 2	2017-04-04
Marker Quantitation In Single Cells In Tissue Sections App 20170082630 - Hendriks; Bart S. ; et al.	2017-03-23
Combination Therapies for Treating Her2-Positive Cancers that are Resistant to Her2-Targeted Therapies App 20170080087 - ESPELIN; CHRISTOPHER ; et al.	2017-03-23
Combination Therapies For Treating Her2-positive Cancers App 20170022290 - MOYO; VICTOR ; et al.	2017-01-26
Combination Therapy For Treating Her2-positive Cancers App 20160250328 - Moyo; Victor ; et al.	2016-09-01
Methods And Compositions For Improving Outcomes Of Liposomal Chemotherapy App 20160184227 - GERETTI; ELENA ; et al.	2016-06-30
Methods And Compositions For Improving Outcomes Of Liposomal Chemotherapy App 20160067182 - GERETTI; ELENA ; et al.	2016-03-10
Combination Therapies For Treating Her2-positive Cancers That Are Resistant To Her2-targeted Therapies App 20160045596 - Geretti; Elena ; et al.	2016-02-18
Dosage And Administration For Preventing Cardiotoxicity In Treatment With Erbb2-targeted Immunoliposomes Comprising Anthracycline Chemotherapeutic Agents App 20160038416 - REYNOLDS; JOSEPH G. ; et al.	2016-02-11
Dosage And Administration For Preventing Cardiotoxicity In Treatment With Erbb2-targeted Immunoliposomes Comprising Anthracycline Chemotherapeutic Agents App 20160038417 - REYNOLDS; JOSEPH G. ; et al.	2016-02-11
Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents Grant 9,226,966 - Reynolds , et al. January 5, 2	2016-01-05
Marker Quantitation In Single Cells In Tissue Sections App 20150111217 - Hendriks; Bart S. ; et al.	2015-04-23
Dosage And Administration For Preventing Cardiotoxicity In Treatment With Erbb2-targeted Immunoliposomes Comprising Anthracyclin Chemotherapeutic Agents App 20140023698 - Reynolds; Joseph G. ; et al.	2014-01-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.